Eurocine Vaccines enters into agreement with Flerie Invest to secure exercise of warrants of series TO 4
Eurocine Vaccines AB (“Eurocine Vaccines” or “the Company”) announces today that the Company has agreed to secure warrants of series TO 4 (“TO 4”) with exercise period between 14 and 28 March 2022. Eurocine Vaccines has agreed to a guarantee commitment regarding TO 4 (so-called “top-down” or “top guarantee”) from the Company's principal owner Flerie Invest AB (“Flerie Invest”) of approximately 50 percent of the issue volume for TO 4. Furthermore, Eurocine Vaccines has entered a subscription commitment of approximately 11.4 percent with Flerie Invest. In total, the Company has thus agreed on